Mod Rheumatol. 2026 May 8:roag038. doi: 10.1093/mr/roag038. Online ahead of print.
ABSTRACT
OBJECTIVE: Systemic inflammation plays a key role in the progression of osteoarthritis (OA). The aim of this study was to explore the association of an emerging systemic inflammation marker, the pan-immune-inflammation value (PIV), with all-cause and cardiovascular disease (CVD) mortality in patients with OA.
METHODS: OA participants from the National Health and Nutrition Examination Survey 1999-2018 were included. PIV was calculated according to the following formula: PIV = (platelet count × neutrophil count × monocyte count)/lymphocyte count. OA was assessed through self-report, and mortality was obtained by matching to the National Death Index.
RESULTS: A total of 3903 participants with OA were included. During the follow-up period, 1032 individuals died, 359 of whom died of CVD. After adjusting for all confounders, lnPIV was positively associated with all-cause and CVD mortality in the OA population (HR 1.273 and 1.364, respectively; p=0.002 and p=0.004). Participants with PIV at Q4 had a significantly increased risk of mortality compared to Q1 (HR 1.439 and 1.506, respectively). These associations all demonstrated nonlinear relationships and were significant only after the inflection point, suggesting a threshold effect rather than a bidirectional pattern. Alcohol consumption influenced the association between PIV and CVD mortality. However, receiver operating characteristic analyses demonstrated the limited predictive value of PIV for long-term mortality.
CONCLUSIONS: Higher PIV was associated with increased risk of all-cause and CVD mortality in US adults with OA. High-quality studies are needed to explore the value of PIV in clinical mortality prediction models.
PMID:42102158 | DOI:10.1093/mr/roag038